A total of eight fellowship places are financed for the Else Kröner Graduiertenkolleg Eicosanoid and Sphingolipid Signalling Pathways in Inflammation, Cancer and Vascular Diseases, two thereof at the Karolinska Institute in Sweden. In cooperation with the Department of Medical Chemistry of the Karolinska Institute, Goethe University in Frankfurt am Main educates doctoral candidates in the areas of molecular medicine, pharmacy and biology. The college was founded in 2010 as the Hans Kröner Graduate School, and shall be funded, following it positive interim evaluation, as the Else Kröner Graduate School until 2018. > Homepage Else Kröner-Graduiertenkolleg
Goethe University in Frankfurt am Main and the Else Kröner-Fresenius Foundation opened the graduate school “Translational Research Innovation – Pharma” (TRIP) in 2012. The graduate school combines preclinical research and clinical development, and works together with interdisciplinary teams on five thematic platforms. The establishment of TRIP is also an important building block for the future development of the Frankfurt House of Pharma. Following a positive interim evaluation the EKFS has confirmed funding for a second three-year period until 2017. > Homepage Translational Research Innovation-Pharma
The Else Kröner-Fresenius-Zentrum für Ernährungsmedizin (EKFZ) was established in 2003 at the Technical University of Munich (TUM) and is the EKFS’s most significant individual activity to date.
Initially, three professorships in the fields of clinical, molecular and paediatric nutritional medicine were funded until 2014, which were dedicated to the following objectives:
Since 2012 EKFS has been supporting the thematic development of the concept, with the addition of the factor of “movement” as another important lifestyle factor for health. Read more
The Else Kröner-Fresenius Foundation funds individual, globally unique registers as an important research resource and a contribution to the investigation of, in some cases, rare diseases. These are systematic collections of standard patient documentation on specific diseases, including the archiving of biopsy or other sample material. These materials are used again and again, e.g. when validating new biomarkers, and their importance often goes far beyond the original issues that were in the foreground when the register was compiled. External cooperation partners also use these libraries.